Aurora Cannabis: Consensus Estimates Point To Flat Quarterly Growth

Aurora Cannabis (TSX: ACB) (NYSE: ACB) announced that they will be reporting their fiscal third quarter financials after market close on March 13th. Analysts have a consensus C$12.58 12-month price target on the company, via a total of 13 analysts, with seven analysts having hold ratings, four analysts having sell ratings and two analysts having strong sell ratings. The street high comes from Bryan Garnier with a C$20 price target, and the lowest target comes from Stifel with a C$7.80 price target.

Twelve analysts have revenue estimates for the third quarter. The mean between all 12 is C$68.94 million; this number has been revised downwards from C$75.24 million at the start of the year. Piper Sandler currently has the highest revenue estimate with C$74.50 million, while the lowest comes from Stifel with a C$60 million estimate.

Only five analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 43.90%, with this number being revised downwards from 47.55% at the start of the year. Street high goes to Cantor Fitzgerald with a 53% estimate and the lowest sits at 31.50%

Onto EBITDA estimates, there are currently 10 analysts who have third quarter EBITDA estimates. The mean is currently (C$10.30) million, with this number being down from C$1.76 million at the start of the year. Street high goes to MKM Partners with a $0 million EBITDA estimate and the lowest being from Needham & Co with a (C$13.61) million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Building the $500M-a-Year Gold Mine | Victor Cantore – Amex Gold Mining

Building the Next 500,000-Ounce Gold Producer | Stephen Soock – Heliostar Metals

This Gold Explorer Is Making Its Biggest Bet | Brian Miller – Astra Exploration

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Facebook Blows Analyst Expectations Away With Strong Results

Facebook Inc (NASDAQ: FB) opened 8% higher Thursday morning, reaching record highs and closing in...

Saturday, May 1, 2021, 03:34:00 PM

Canaccord Initiates Coverage On Uranium Royalty Corp With $1.60 Price Target

This morning Canaccord Genuity’s Katie Lachapelle initiated coverage on Uranium Royalty Corp (TSXV: URC) with...

Tuesday, September 8, 2020, 03:17:18 PM

Aurora Posts Flat Quarterly Revenue Growth In Q2 2022

Aurora Cannabis (TSX: ACB) this evening reported its second quarter financial results. The firm reported...

Thursday, February 10, 2022, 05:25:34 PM

GoGold: BMO Lowers Target Price After Production Miss

On January 5th, GoGold Resources Inc. (TSX: GGD) announced its production data for the fiscal...

Friday, January 7, 2022, 02:49:00 PM

Canopy Growth: Analysts Anticipate Q1 Revenues Of $149 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal...

Tuesday, August 3, 2021, 03:28:00 PM